compound 17 [PMID: 38477582]   Click here for help

GtoPdb Ligand ID: 13346

Compound class: Synthetic organic
Comment: This compound was designed at Mirati Therapeutics, to selectively inhibit PI3Kα with the H1047R mutation that is prevalent in select solid tumours [1]. This approach spares the activity of wild type PI3Kα that is required for normal cellular functions.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 109.03
Molecular weight 467.47
XLogP 2.73
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CN2C(=NC(=C(C#N)C2=O)N3CCC(CC3)(F)F)C(=C1)[C@@H](C)NC4=C(C=CC=C4)C(=O)O
Isomeric SMILES CC=1C=C(C2=NC(=C(C(=O)N2C1)C#N)N3CCC(CC3)(F)F)[C@@H](C)NC4=CC=CC=C4C(=O)O
InChI InChI=1S/C24H23F2N5O3/c1-14-11-17(15(2)28-19-6-4-3-5-16(19)23(33)34)21-29-20(18(12-27)22(32)31(21)13-14)30-9-7-24(25,26)8-10-30/h3-6,11,13,15,28H,7-10H2,1-2H3,(H,33,34)/t15-/m1/s1
InChI Key OIVDIJHGKFXNJF-OAHLLOKOSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

Bioactivity Comments
Induces tumour regression in the mouse HCC1954 xenograft model.
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha Hs Allosteric modulator Inhibition 9.0 pIC50 - 1
pIC50 9.0 (IC50 1x10-9 M) [1]
Description: Inhibition of AKT phosphorylation in T47D breast cancer cells harbouring PI3KαH1047R, using a AlphaLISA assay